Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 4,237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Recruiting No phase listed Observational

Detecting HPV DNA in Anal and Cervical Cancers

NCT04857528
View directory record Official record
Conditions
Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, Uterine Cervical Cancer
Interventions
Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test), Testing Archival Tumor Tissue, Physical Exam, Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)
Radiation · Other · Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 29, 2026, 8:42 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

NCT07843498
View directory record Official record
Conditions
Obesity or Overweight
Interventions
Petrelintide, Placebo
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Anniston, Alabama • Port Orange, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

NCT02480114
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions
Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

NCT01295814
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Adalimumab, inactive drug
Drug · Other
Lead sponsor
ICStudy, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

NCT01360645
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712 + ADT, Placebo + ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Arcadia, California • Beverly Hills, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

NCT02970292
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 2 Interventional

Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

NCT02473016
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Carbon Dioxide Drug Delivery System (CDDS)
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

NCT00962637
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, AndroGel, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

NCT00004412
View directory record Official record
Conditions
Skin Ulcers, Sickle Cell Anemia
Interventions
Arginine Butyrate, Standard local care dressing
Drug · Other
Lead sponsor
Susan P. Perrine
Other
Eligibility
16 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 29, 2026, 8:42 PM EDT
Active, not recruiting Phase 2 Interventional

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

NCT04476953
View directory record Official record
Conditions
Covid19
Interventions
Placebo, Fisetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 29, 2026, 8:42 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

NCT06271265
View directory record Official record
Conditions
Postoperative Pain
Interventions
EXPAREL, bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
0 Years to 6 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

NCT02008565
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Loperamide, Placebo, Anal exercises with biofeedback, Usual Care
Drug · Behavioral
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional

Phase 3 Study of EBI-005 in Dry Eye Disease

NCT01998802
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Active Comparator EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
45
States / cities
Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

NCT05089851
View directory record Official record
Conditions
Wrinkles, Photoaging, Fine Lines
Interventions
Onabotulinumtoxin A, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Combination Product
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Coralville, Iowa • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 29, 2026, 8:42 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

NCT01208129
View directory record Official record
Conditions
Onychomycosis
Interventions
NAB001, Placebo control
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tucson, Arizona • Phoenix, Arkansas • Rogers, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 29, 2026, 8:42 PM EDT
Terminated Phase 2 Interventional Results available

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

NCT05814666
View directory record Official record
Conditions
HNSCC
Interventions
Danvatirsen, Pembrolizumab
Drug
Lead sponsor
Flamingo Therapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Tucson, Arizona • Irvine, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 29, 2026, 8:42 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

NCT00414466
View directory record Official record
Conditions
Chronic Intractable Pain
Interventions
Intraspinal Gabapentin
Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

NCT02024386
View directory record Official record
Conditions
Hypertension, Pulmonary, Altitude Sickness
Interventions
Riociguat
Drug
Lead sponsor
Richard Moon
Other
Eligibility
18 Years to 40 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 29, 2026, 8:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

NCT02515669
View directory record Official record
Conditions
Muscular Dystrophy (DMD)
Interventions
RO7239361, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 10 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Uproleselan, Placebo, Melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT03015402
View directory record Official record
Conditions
Pulmonary Hypertension Secondary, Heart Failure
Interventions
Sodium Nitrite, Placebo Oral Capsule
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 29, 2026, 8:42 PM EDT